Clinical trial
Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy…
NCT00051454 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00051454 |
|---|---|
| Title | Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults |
| Official title | A Randomised, Placebo-Controlled, Double-Blind, Phase I/IIa Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic DNA Prime-rFPV Boost HIV Vaccination Strategy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | HIV DNA plasmid vaccine plus recombinant fowlpox vector |
| Enrollment | 24 |
| Start date | Mar 1, 2003 |
| Completion | Feb 1, 2005 |
| First posted | Jan 13, 2003 |
| Last update posted | Aug 27, 2007 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: